KMPH - KemPharm, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.2020
+0.0008 (+0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2012
Open0.2175
Bid0.1801 x 900
Ask0.0000 x 800
Day's Range0.2027 - 0.2199
52 Week Range0.1800 - 2.0000
Volume483,330
Avg. Volume2,106,504
Market Cap10.238M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its investigational product candidate, KP415, to the U.S. Food and Drug Administration (FDA). KP415 is KemPharm’s product candidate for the treatment of attention deficit hyperactivity disorder (ADHD) which contains serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH).

  • GlobeNewswire

    KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

    KP415 NDA Remains on Track for Q1 2020 Submission CELEBRATION, Fla., Feb. 28, 2020 -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the.

  • GlobeNewswire

    Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company’s request to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market effective today, January 15, 2020. Further, the Hearings Panel has also granted the Company an extension until May 13, 2020, to regain compliance with the Market Value of Listed Securities (“MVLS”) continued listing requirement of The Nasdaq Capital Market, conditioned upon achievement of certain milestones included in a plan of compliance which the Company previously submitted to the Hearings Panel.

  • GlobeNewswire

    KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced its entry into a December 2019 Exchange Agreement and Amendment to Facility Agreement, Senior Secured Convertible Notes and Warrants (the December 2019 Exchange Agreement) with Deerfield (as defined below) and Delaware Street Capital (DSC, as further defined below). Under the December 2019 Exchange Agreement, the Company will effect a series of transactions, which, among other things, will push the principal and interest payments on outstanding debt in principal amount of $77.7 million to a new maturity date of March 31, 2021.

  • GlobeNewswire

    KemPharm Reports Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET CELEBRATION, Fla., Nov. 14, 2019 -- KemPharm, Inc..

  • GlobeNewswire

    KemPharm to Report Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled forThursday, November 14, 2019, 5:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2019 -- KemPharm, Inc..

  • GlobeNewswire

    KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a commercial update related to its FDA-approved prodrug product, APADAZ® (benzhydrocodone and acetaminophen, or APAP, tablets), which has been licensed to KVK-Tech, Inc. (“KVK-Tech”) for commercialization. Specifically, KVK-Tech has informed KemPharm that APADAZ and its authorized generic (AG-APADAZ) will be available nationally beginning in November 2019. In addition, KemPharm provided updates on formulary access for AG-APADAZ, including its inclusion on the preferred drug lists for the respective Medicaid plans in Alabama and Utah.

  • GlobeNewswire

    KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that study results demonstrating the ability of KP415 to be administered without regard to food and via alternative dosing methods was presented at the 66th Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting in Chicago.  KP415 is KemPharm’s prodrug product candidate of d-methylphenidate (d-MPH) being developed for the treatment of attention deficit hyperactivity disorder (ADHD). On September 3, 2019, KemPharm entered into a license and collaboration agreement with an affiliate of Gurnet Point Capital (“GPC”) for the commercial rights to KP415 and related development products.

  • GlobeNewswire

    KemPharm Provides Updates Regarding its Board of Directors

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019, Danny L. Thompson provided notice of his resignation from the Company’s Board of Directors, citing personal health reasons. Following Mr. Thompson’s resignation, the Board has appointed Richard W. Pascoe, the Company’s Lead Independent Director and a standing member of the Audit Committee, to serve as Chairman of the Audit Committee, effective September 18, 2019.

  • GlobeNewswire

    KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

    CELEBRATION, Fla., Sept. 17, 2019 -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,.

  • GlobeNewswire

    KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

    KemPharm also announced its entry into a debt exchange agreement and other amendments to its senior debt facility (the Exchange Agreement) with funds managed by Deerfield Management Company, L.P. (Deerfield), potentially reducing its debt outstanding by up to $22 million over a period of 240 days, and up to $30 million, in the aggregate. Under the terms of the License Agreement, KemPharm will receive an upfront payment of $10 million, and is eligible to receive pre-approval cost reimbursements, regulatory milestone payments both prior to and upon approval, and sales milestone payments totaling as much as $483 million, as well as tiered royalty payments on a product-by-product basis for net sales under the License Agreement.  These royalty rates range, on a product-by-product basis, from a percentage in the high single digits up to the mid-twenties for U.S. net sales, and a percentage in the low to mid-single digits of net sales in each country outside of the U.S.

  • GlobeNewswire

    KemPharm Reports Second Quarter 2019 Results

    CELEBRATION, Fla., Aug. 13, 2019 -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today.

  • GlobeNewswire

    KemPharm Reports First Quarter 2019 Results

    Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDAProvided Update on APADAZ® Formulary AdoptionAnnounced FDA Approval of sNDA for Two Additional.

  • GlobeNewswire

    KemPharm Completes KP415 Pre-NDA Meeting with FDA

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") for KP415, KemPharm’s investigational attention-deficit/hyperactivity disorder (ADHD) product candidate that contains serdexmethylphenidate (a prodrug of d-methylphenidate) and d-methylphenidate.